Aquestive Therapeutics Inc (AQST, Financial) is set to release its Q3 2024 earnings on Nov 4, 2024. The consensus estimate for Q3 2024 revenue is $12.68 million, and the earnings are expected to come in at -$0.13 per share. The full year 2024's revenue is expected to be $58.01 million and the earnings are expected to be -$0.46 per share. More detailed estimate data can be found on the Forecast page.
Aquestive Therapeutics Inc (AQST, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Aquestive Therapeutics Inc (AQST) for the full year 2024 have increased from $49.79 million to $58.01 million, and for 2025, they have increased from $57.49 million to $57.76 million. Earnings estimates for the full year 2024 have increased from -$0.49 per share to -$0.46 per share, while for 2025, they have declined from -$0.39 per share to -$0.46 per share.
Aquestive Therapeutics Inc (AQST, Financial) Reported History
In the previous quarter of 2024-06-30, Aquestive Therapeutics Inc's (AQST) actual revenue was $20.10 million, which beat analysts' revenue expectations of $12.38 million by 62.35%. Aquestive Therapeutics Inc's (AQST) actual earnings were -$0.03 per share, which beat analysts' earnings expectations of -$0.113 per share by 73.45%. After releasing the results, Aquestive Therapeutics Inc (AQST) was up by 0.88% in one day.
Aquestive Therapeutics Inc (AQST, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 8 analysts, the average target price for Aquestive Therapeutics Inc (AQST) is $9.56 with a high estimate of $15 and a low estimate of $5.50. The average target implies an upside of 73.86% from the current price of $5.50.
Based on GuruFocus estimates, the estimated GF Value for Aquestive Therapeutics Inc (AQST, Financial) in one year is $1.31, suggesting a downside of -76.18% from the current price of $5.50.
Based on the consensus recommendation from 8 brokerage firms, Aquestive Therapeutics Inc's (AQST, Financial) average brokerage recommendation is currently 1.8, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
